More Weight Loss Solutions

Archives

Archive for the ‘Weight Loss’ Category

Ree Drummond wants to set the record straight: She has not used any weight loss medications or supplements during her her weight loss journey.

On Tuesday, the Pioneer Woman star, 54, announced on Facebook that she was updating a 2021 blog post where she shared what does and doesnt do to lose weight. In the update, she wrote, I did not take Ozempic, Wegovy, or similar medications.

Ozempic or Wegovy are FDA-approved prescription medications for people with type 2 diabetes and obesity. They are brand names for semaglutide, which works in the brain to impact satiety, and is the latest Hollywood trend as many use the drugs off-label for weight loss.

I support anyone who has success using the above medications. I know they have been an absolute godsend for so many people; I have friends who've experienced incredible results, Drummond said, noting that she didnt know about the drugs when she began her weight loss journey in January 2021.

I simply didn't know those drugs existed then, so I dove in using all the methods below, she explained, referring to the blog posts mention of changing her diet, fitness and lifestyle habits.

Today, even though I have gained a few pounds up and down, I still have not chosen that option, she said of the popular weight loss injections. But you'll never hear a second of judgment from me about people who choose that direction!

Additionally, Drummond said she hasnt taken any weight-loss gummies or other supplements. However, she warned that she is one of the many public figures whose name and image have been used in fake advertisements as part of a celebrity endorsement fraud scheme.

Monica Schipper/Getty Images for The Pioneer Woman Magazine

Never miss a story sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.

Back in October 2023, the Food Network star opened up about maintaining a 50-lb. weight loss for nearly three years, telling Today that her strategies were straightforward.

The biggest takeaway, which I dont always adhere to, is trying not to waste calories, Drummond told the outlet. I could eat a plate of delicious food with different elements and colors and flavor, or I could eat a donut.

She explained that she tackled [her health] from different directions. She cut out alcohol, started eating more protein and vegetables, and introduced daily exercise into her routine, like walking her dogs and using at-home gym equipment.

Im an impatient home exerciser, so the rowing machine was probably my favorite," said Drummond, who admitted her relationship with exercise isn't perfect. Right now, the rowing machine is a clothes rack."

In general, Drummonds routine emphasizes a forgiving diet and exercise plan that doesnt omit entire food groups or adhere to strict workout schedules.

I think what Ive done over the past two years is knowing that I dont want to push things away or say no to foods. I upped my movement a bit. I take a couple extra walks with the dogs each week. I make sure to get on the rowing machine at least once a day, especially through November and December, she said at the time.

See the original post here:
Ree Drummond 'Did Not Take Ozempic, Wegovy' To Lose Weight - PEOPLE

Comments Off on Ree Drummond ‘Did Not Take Ozempic, Wegovy’ To Lose Weight – PEOPLE
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Wegovy, the blockbuster weight loss drug, is now approved for a new use: reducing the risk of heart attacks, strokes and cardiovascular-related death in adults who have heart disease and are overweight or have obesity.

The new indication, which the Food and Drug Administration announced on Friday, will pave the way for even more patients to use the sought-after medication and could potentially broaden insurance coverage. The drugs maker, Novo Nordisk, said it had also filed for an expanded label in the European Union.

The F.D.A. approval was based on the results of a large study of over 17,000 adults ages 45 and older. Researchers either gave participants shots of Wegovy or a placebo and followed them for several years. Among those who received placebo shots, 8 percent had a heart attack, stroke or died from a cardiovascular event, compared with 6.5 percent of participants who took Wegovy.

While its not clear whether the effect of the drug is purely from weight loss, or whether the drug has other heart benefits, the data shows that when you treat obesity seriously in people who have a high burden of disease, you can get really good outcomes, said Dr. Melanie Jay, director of the N.Y.U. Langone Comprehensive Program on Obesity.

The new indication comes at a challenging moment for the relatively new class of drugs that includes Wegovy and Ozempic. The medications are highly effective, but costly: Wegovy has a list price of over $1,300 for about a months supply. And doctors typically say patients may need to take these drugs for the rest of their lives. Those cost considerations have led some employers and health plans to stop covering the medications, or to limit access or cap spending amid soaring demand.

The updated label will likely deepen the pressure on payers and employers to cover the drugs. Many of the patients who could qualify for Wegovy under the new indication may be on Medicare, said Dr. Andrew Kraftson, clinical associate professor in the division of metabolism, endocrinology and diabetes at Michigan Medicine.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Read this article:
Wegovy Approved By FDA to Reduce Heart Attack Risk - The New York Times

Comments Off on Wegovy Approved By FDA to Reduce Heart Attack Risk – The New York Times
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Published: Mar 13, 2024 By Greg Slabodkin, Heather McKenzie, Tyler Patchen

The weight loss market is the gift that keeps on givingat least for Novo Nordiskas Wegovy continues to demonstrate its prowess with label expansion.

Also discussed: biosimilar approvals for Fresenius Kabi, and Sandoz.

More news at the forefront of Alzheimer's treatment: Eli Lilly's donanemab decision date got pushed and now the FDA wants to discuss the drugs safety and efficacy at an upcoming adcomm.

And finally, politics: President Biden's State of the Union address ruffles feathers as he strikes out at Big Pharma and drug prices, and how the industry is reacting to the election.

Greg Slabodkin is the News Editor at BioSpace. You can reach him atgreg.slabodkin@biospace.com. Follow him onLinkedIn.

Heather McKenzie is a senior editor atBioSpace. You can reach her atheather.mckenzie@biospace.com. Follow her onLinkedIn.

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him onLinkedIn.

> Listen on Spotify

> Listen on Apple podcasts

> Listen on Amazon Music

> Listen on iHeart

See the rest here:
The Skinny on Weight Loss, Donanemab and the State of the Union - BioSpace

Comments Off on The Skinny on Weight Loss, Donanemab and the State of the Union – BioSpace
Mar 14th, 2024 | Filed under Weight Loss
Tags:

The U.S. Food and Drug Administration approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind that could dramatically expand the already huge market for the drug.

Wegovy, which has the same active ingredient as diabetes drug Ozempic, already had FDA approval to treat patients who are obese or overweight. It has become a cultural sensation and a blockbuster, bringing in billions of dollars in revenue for its manufacturer, Novo Nordisk.

Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, John Sharretts, a director in the FDAs Center for Drug Evaluation and Research, said in a statement Friday.

We recognize how important this moment is for the millions of people who live with excess weight or obesity and known heart disease, and we will continue to advance options that put their needs first, Doug Langa, head of Novo Nordisks North American operations, said in a statement.

The FDAs expansion of Wegovys regulatory label comes after a closely watched clinical trial last year found that the drug dramatically reduced the risk of heart problems for overweight people. In a five-year study of more than 17,600 patients, Wegovy cut the risk of strokes, heart attacks and other cardiovascular problems by 20 percent among overweight adults with a history of heart disease. Expanding Wegovys regulatory label could also entice more insurers to cover the pricey drug, according to researchers and Wall Street analysts.

The result will pressure insurers and the federal government to cover this medication, said Harlan Krumholz, a cardiologist at the Yale School of Medicine. It will be increasingly difficult to deny people access to these medications, as this is not about appearance but concerns health.

Wegovy, whose active ingredient is semaglutide, works by mimicking a naturally occurring hormone called glucagon-like peptide 1 (GLP-1). It slows the emptying of the stomach and sends a signal of fullness to the brain.

Some financial analysts say GLP-1 drugs, as theyre sometimes called, including Eli Lillys tirzepatide-based products Mounjaro and Zepbound, could become the biggest-selling class of drugs ever. In a December report, Goldman Sachs compared Novo Nordisk and Eli Lillys innovations with Amazon and Apple, saying they have the opportunity to expand into categories far beyond what most investors are currently contemplating.

But their dominance is far from assured, as competitors large and small are creating their own weight-loss drugs that rival the market-leading drugs. In addition, the high cost of the drugs the list price for a months supply of Wegovy costs more than $1,300 means some employers and insurance plans have been reluctant to cover the medications. Undesirable side effects, including nausea and vomiting, can also limit how long patients are willing to take the weekly injectable drug.

Demand for Wegovy has been so intense that Novo Nordisk has struggled to churn out enough, leading the FDA to declare the drug in shortage beginning in March 2022. Novo and Lilly are racing to secure enough manufacturing power to keep up with the growing demand for their marquee products.

Denmark-based Novo said in January that it had begun boosting supplies of Wegovy in the United States, after curtailing starting doses last year to ensure there would be enough for existing patients. Then in February, Novos controlling shareholder acquired Catalent, a manufacturer based in New Jersey, an unusual move that would give the drugmaker three new manufacturing plants.

On the front lines of battling obesity, some doctors caution that the FDAs decision does not mean insurers will quickly embrace paying for the drugs. At the Stanford Lifestyle and Weight Management Center at Stanford University, insurers routinely deny patients who qualify for the weight-loss drugs, often for opaque reasons, said Dan Azagury, the centers medical director.

He said he doesnt expect that to change, but the FDAs decision on Wegovy gives physicians one more leg to stand on when they are trying to justify to insurance companies that this treatment is the right treatment.

Dana P. Goldman, an economist at the University of Southern California, said insurers will eventually be able to negotiate lower prices for GLP-1 drugs. We are going to see a very steep discount on these products in the next couple years, he said, adding, The challenge will be scaling up production.

View post:
FDA approves weight-loss drug Wegovy to reduce heart-disease risks - The Washington Post

Comments Off on FDA approves weight-loss drug Wegovy to reduce heart-disease risks – The Washington Post
Mar 14th, 2024 | Filed under Weight Loss
Tags:

When I was ordering birthday cakes for a fictitious person, I knew it was time to do something," says WWL Radio host Tommy Tucker.

NEW ORLEANS Tommy Tucker has been a radio personality since the 1980s.

Slowly over the decades, his weight rose, to the point where a doctor told him he was prediabetic.

Many fad diets had failed.

So, he decided to try the latest medication after doing an interview about it on his show.

You've heard his familiar voice for decades, but you may not have recognized the person behind it. And WWL Radio morning host Tommy Tucker said he got to the point where he didn't recognize himself either.

I kept getting bigger pants, and I'd start wearing Hawaiian shirts without tucking them in, and I'd think, Ya know what, that doesn't look that bad, Tucker remembers.

And he felt helpless over his extreme sugar cravings.

I would have weekends built around bakeries. When I was ordering birthday cakes for a fictitious person, I knew it was time to do something.

That time came when the scale hit 230 pounds. With every other fad diet and his exercise routine, his weight would yo-yo up and down. And then he did an interview on his show about the GLP-1 injections for diabetes, or weight loss. And what doctors call "food noise" went instantly away.

I didn't have that constant craving for food. I wasn't going to graze in the kitchen, and just open the refrigerator looking for something to eat. And the other thing was that I'd get full, he said.

When asked isn't that freedom in some ways?

He replied, Absolutely. It's freedom. I felt like, it's like freedom from an addiction almost.

To demonstrate how much extra weight he was carrying around all the time, he picked up two 40-pound dumbbells that he uses to exercise. Tommy lost 80 pounds.

And I'm doing things now that I never would be able to do before, cleaning out the attic for example. Something as simple as that. I love to exercise now. Yard work used to wear me out. Every year I would think is this the last year I'll be able to do the yard work.

When Tommy got down to 150 pounds, he went off of the medication and quickly realized what doctors had been saying about the drug. It helps regulate hormones, and physiology in people where they are dysregulated.

And I noticed the cravings coming back, and the weight crept from 150 to 160 because I was starting to spend a lot of time at bakeries again, Tucker remembers.

He understands, just like someone who needs hormone replacement, or insulin replacement for a chronic condition, he will need treatment of Mounjaro along with his regular exercise routine.

Constantly. I thought it was weakness. I thought it was just a lack of determination and willpower, but I realized it's not it's the way I'm wired up.

Mounjaro is a prescription for people with diabetes. The weight management version is called Zepbound, and is also by prescription only.

Get breaking news from your neighborhood delivered directly to you by downloading the new FREE WWL-TV News app now in theIOS App StoreorGoogle Play.

See the rest here:
Local radio personality finds freedom from food addiction in using weight-loss medication - WWLTV.com

Comments Off on Local radio personality finds freedom from food addiction in using weight-loss medication – WWLTV.com
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Danish pharma giant Novo Nordisk teased promising early-stage trial results of its experimental weight loss pill amycretin last week, resulting in the companys stock surging.

Does Novo Nordisk already have the next Ozempic?

On Mar. 7, the company told investors that a small trial of the pill found that it could be twice as effective as the companys current blockbuster weight loss drug.

Does Novo Nordisk already have the next Ozempic?

A day later, Novo Nordisk CEO Lars Fruergaard Jrgensen said that amycretin could develop into a best-in-class medicine.

Novo Nordisk is credited with ushering in the weight loss drug revolution after the FDA approved its drug Wegovy in 2021. Before that, the firms diabetes medication Ozempic had become known for its slimming side effects. Since then, skyrocketing demand for Ozempic and Wegovy has turned Novo Nordisk into the most valuable company in Europe, surpassing luxury conglomerate LVMH last year. Sales of the medications even helped boost Denmarks GDP by 1.8% in 2023.

Now, news of this next-gen weight loss drug lifted the companys market cap above Teslas and made it the12th-most valuable company in the world.

Here is everything you need to know about the powerful pill that has whipped investors into a frenzy.

The main difference between amycretin and Wegovy is that the former stimulates two different gut hormones while the latter only stimulates one.

In addition to stimulating glucagon-like peptide 1 (GLP-1), like Wegovy, amycretin also stimulates amylin. Both GLP-1 and amylin impact blood sugar levels and appetite.

Another major difference between the two medications, is that amycretin is taken once daily as a pill and Wegovy is a weekly injection.

A small ongoing trial of the drug on obese Japanese men found that the pill helped users lose an average of 13% of their body weight after 12 weeks. For comparison, a larger clinical trial of Wegovy found that it helped users lose about 15% of their body weight over 68 weeks.

Its important to note that larger phase II, III, and IV trials, involving thousands more participants, could return different results.

Jrgensen told CNBC on Mar. 8, that he doesnt expect amycretin to completely replace Wegovy in the market.

We believe in the future, there will be different segments of anti-obesity treatments, different patients having different preferences, Jrgensen said. Some will prefer an injectable. And we really believe that a once-weekly injectable is a very convenient offering.

Novo Nordisk said its will begin a phase II trial of the drug in the second half of the year, however, results of the trial wont be available until early 2026.

Still, the companys head of development Martin Holst Lange told Reuters the drug could launch this decade.

I never commit to timelines but I would be very comfortable to say at the very least within this decade, Lange told the outlet.

View post:
Ozempic maker Novo Nordisk is working on a weight loss pill that's even more powerful. Here's what to know - Quartz

Comments Off on Ozempic maker Novo Nordisk is working on a weight loss pill that’s even more powerful. Here’s what to know – Quartz
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Ozempic, Wegovy, and related weight loss drugs have become some of the worlds most talked about medications in a remarkably short amount of time.

Much of the conversation centers around celebrities who credit the drugs with helping them shed weight and look trimmer, sometimes very quickly.

But doctors and researchers are largely focused on whether the medications may be an important new tool for treating the epidemic of obesity and related conditions that can cause serious health problems including a greater risk of cancer.

There are at least 13 types of cancer, includingbreast, prostate, endometrial, and others that we know are linked to obesity, saysNeil Iyengar, MD, a breast cancer oncologist at Memorial Sloan Kettering Cancer Center (MSK) and a nationally recognized expert on the relationship ofobesity, metabolic health, and cancer.

Separate from obesity, Dr. Iyengar adds, having higher levels of body fat is associated with an increased risk of several forms of cancer.

He continues: I foresee that this class of drugs will revolutionize obesity and the cancer burden that comes with it, if people can get access. This really is an exciting development.

Dr. Iyengar cautions that these are early days for these medications with much research yet to do. However, Many patients ask me about these medications, he says. Here, he provides answers to the questions his patients ask most often.

The best known right now are:

These are known as GLP-1 agonists. They activate the GLP-1 receptor that stimulates the production of insulin, which regulates blood sugar, as well as delivering several other effects.

Because they affect insulin, these medications were originally developed to treat diabetes. Ultimately, their weight loss effect was recognized.

Its important to know that the current Food and Drug Administration (FDA) indication (or guidance) for being treated with one of these drugs is obesity plus a metabolic disorder related to obesity, like diabetes. A cancer diagnosis currently does not qualify as a reason for treatment with these drugs. MSK is conducting research to determine if cancer should be added as a reason for treatment with these medications.

They do, and the weight loss is even better when combined with healthy lifestyle choices.

There have been weight loss drugs for a long time, but they provided only moderate weight loss and had a lot of side effects. This new class of drugs are much more successful in treating obesity and inducing weight loss, and have manageable side effects.

Think of it as constantly putting you in a post-meal state, where you feel full and arent hungry, so you dont feel the urge to eat. This happens through several different mechanisms, some of which are not fully understood. These include the following hormones:

All these factors work together, and there is direct stimulation of the brain telling you that you dont have cravings and feel full just like after a big meal.

We know obesity and even high body fat puts people at greater risk for multiple forms of cancer. It can be a challenge to get a healthier body composition for many people, and these medications can help jump-start the effort.

By reducing food cravings, these drugs can lower the consumption of highly processed food, which is particularly bad for overall health, including cancer risk. There is also evidence to suggest cravings for alcohol are lowered.

Lifestyle modifications are crucial a medication alone is not a long-term fix. For people with cancer, I especially recommend a high-fiber, plant-forward diet and consistent exercise. For people with breast cancer, theMSK Healthy Living Program helps to implement these lifestyle recommendations. Getting started with those kinds of lifestyle changes may now be easier for some people thanks to an appropriate use of the new weight loss medications.

We simply dont have the data for somebody who has just been diagnosed with cancer. I also worry about anything that could disrupt urgent treatments likechemotherapy orradiation therapy orimmunotherapy at the beginning of cancer therapy. For instance, there can be gastrointestinal side effects with these weight loss drugs, and that could interfere with some cancer treatments.

On the other hand, if someone has been on cancer treatment for a couple months and is tolerating it well, it may be fine to use these weight loss medicines. For people on long-termhormonal therapy, weve anecdotally seen that use of concurrent weight loss medications appears to be feasible. In fact, some patients quit taking their hormone therapy because it can be associated with weight gain, and the new weight loss medications might be a solution. Of course, anyone on cancer therapy and interested in starting a weight loss medication should first check with their oncologist.

We definitely need clinical trials to determine the safest and most effective approach to medical weight loss in the setting of cancer treatment.

Of course, people would need to discuss the best option with their care team.

There can certainly be gastrointestinal side effects, including nausea and vomiting for some people, which are usually manageable.

Some research has also raised the risk of more serious side effects, including:

This side effect was quite rare. In fact, the FDA concluded that there were no concerns about suicidal ideation caused by these drugs. However, if a person taking these drugs notes a depressed mood or change in anxiety level, they should discuss it immediately with their provider.

If you or someone you know may be experiencing a mental health crisis or contemplating suicide, call or text 988. In emergencies, call 911, or seek care from a local hospital or mental health provider.

Its worth noting that some research suggests the medications may actually protect against some forms of cancer, including colorectal cancer, for reasons that go beyond reducing obesity. However, much more research is needed at this point, this is just an interesting hypothesis.

Overall, Im very excited about the development of this class of drugs as a new and effective tool, in addition to lifestyle optimization, for reducing the health risks associated with obesity and metabolic disorders.

Read the rest here:
Cancer Benefits and Risks from Ozempic, Wegovy and Other Weight Loss Drugs - On Cancer - Memorial Sloan Kettering

Comments Off on Cancer Benefits and Risks from Ozempic, Wegovy and Other Weight Loss Drugs – On Cancer – Memorial Sloan Kettering
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Access to this page has been denied because we believe you are using automation tools to browse the website.

This may happen as a result of the following:

Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.

Reference ID: #20b0177a-e1ce-11ee-97c3-638d608eb46f

See the rest here:
Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound - Investor's Business Daily

Comments Off on Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound – Investor’s Business Daily
Mar 14th, 2024 | Filed under Weight Loss
Tags:

BlueSleep, a specialty care digital platform focused on snoring and sleep apnea, is partnering with Shapely, a Los Angeles-based virtual weight loss and wellness clinical pathway, to expand patient access to the platforms.

The partnership helps BlueSleeps patients quickly access Shapelys evidence-based clinical pathway to reduce weight and improve wellness, while Shapelys patients get immediate access to BlueSleeps digital platform to quickly and affordably diagnose and treat snoring and sleep apnea.

Shapely offers patients an affordable and accessible monthly subscription model that provides expert clinical advice in combination with lifestyle changes and weight loss medications such as Wegovy (Ozempic), Zepbound (Mounjaro), and Saxendra (Victoza), among others.

BlueSleep offers same-day scheduling with sleep specialists, home sleep tests, and oral advancement devices and CPAP. The company accepts all major medical insurance and offers self-pay discounts.

The care partnership with Shapely is about saving lives by giving weight-loss patients faster access to sleep apnea treatment, says Jordan Stern, MD, founder and CEO of BlueSleep, in a release. Obese people have severe apnea at twice the rate of normal-weight individuals. Its imperative they seek treatment to reduce their chances of hypertension, diabetes, heart disease, fatigue, and sexual dysfunction.

Justin Zaghi, MD, founder and CEO of Shapely, adds in a release, Shapelys care partnership with BlueSleep furthers our mission to help patients lose weight, achieve their best shape, and live longer, more productive lives. Both companies are clinically driven to improve access to affordable health, making this partnership a win-win-win for both companies and patients.

Photo132527501Alphaspirit|Dreamstime.com

Read more:
Partnership Ups Access to Sleep Medicine and Weight-Loss Care - Sleep Review

Comments Off on Partnership Ups Access to Sleep Medicine and Weight-Loss Care – Sleep Review
Mar 14th, 2024 | Filed under Weight Loss
Tags:

Novo Nordisk CEO Lars Fruergaard Jrgensen.

Novo Nordisk CEO Lars Fruergaard Jrgensen said Friday that the companys experimental weight loss pill, Amycretin, could develop into a best-in-class medicine. His comments on CNBC came a day after the companys stock surged following the announcement of promising results for the drug. That sent Novo Nordisks market cap past Teslas and made it the 12th-most valuable company in the world.

Does Novo Nordisk already have the next Ozempic?

The drug maker told investors on Thursday that Amycretin helped users lose an average of 13% of body weight after 12 weeks in an early-stage trial. By comparison, patients on the diabetes weight loss drugs Ozempic and Wegovy, both of which are injections, lose about 6% of their weight in 12 weeks.

Jrgensen told CNBC on Friday that the he doesnt expect Amycretin to completely replace Wegovy in the market.

We believe in the future, there will be different segments of anti-obesity treatments, different patients having different preferences, Jrgensen said. Some will prefer an injectable. And we really believe that a once-weekly injectable is a very convenient offering.

Jrgensen also said the gap between demand for weight loss drugs and the supply is significant and could take the industry years to close.

He pointed out that there are more 100 million people with obesity in the U.S. alone. Novo Nordisk currently only serves a small population of that group, about 1 million.

Itll take quite some years before the industry has scaled up supplies to be able to meet this very strong demand, Jrgensen said.

Novo Nordisk announced in February that it has acquired three facilities from its companys largest shareholder Novo Holdings for $11 billion in an effort to address a shortage of Wegovy. The deal was made in connection with Novo Holdingss acquisition of the drug manufacturing company Catalent. Novo Nordisk said in a statement that the acquisition will increase the companys production capacity from 2026 and onwards.

Since May 2023, Novo Nordisk has been limiting starter doses of Wegovy to ensure there is enough supply for patients already on the drug.

See the article here:
Ozempic maker Novo Nordisk's new weight loss pill could be 'best-in-class,' CEO says - Quartz

Comments Off on Ozempic maker Novo Nordisk’s new weight loss pill could be ‘best-in-class,’ CEO says – Quartz
Mar 14th, 2024 | Filed under Weight Loss
Tags:
Weight Loss Solutions
matomo tracker